BioNTech, Pfizer say they expect to have COVID-19 vaccine data for young children this quarter

BioNTech SE BNTX, -2.37% and Pfizer Inc. PFE, +1.45% said Tuesday that they expect to share data from a clinical trial evaluating their COVID-19 vaccines in children between the ages of 6 months and 5 years old sometime before the end of June. The announcement was included in a news release stating that the companies requested Food and Drug Administration authorization for a COVID-19 booster dose in children between the ages of 5 and 11 years old. Back in February, BioNTech and Pfizer said that they amended their FDA authorization submission for the youngest children, saying they wanted to wait until data was available showing how three doses of the vaccine worked in this age group. At that time, they estimated that data would be available in early April. There are no COVID-19 vaccines available for children younger than 5 years old at this time. BioNTech’s stock has tumbled 43.6% and Pfizer shares are down 16.9% since the start of the year, while the S&P 500 SPX, +0.21% is down 12.4%.